UMMC Navigation

Cancer

Main Content

GOG 3015

Study title

Phase 3 multicenter randomized study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly diagnosed stage 3 or 4 ovarian cancer

  • Principal Investigator: Dr. Mildred Ridgeway

Purpose

This study will evaluate the effect of an experimental drug in patients with newly-diagnosed ovarian, fallopian tube, and /or primary peritoneal cancer.

Who can participate

Those eligible to participate in this study include:

  • 18 years or older women with newly diagnosed Stage III or Stage IV ovarian, fallopian tube, or primary peritoneal cancer.

For more information

  • Sandra Powe
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 984-1965
  • IRB Number: 2017-0109